Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

Fiona Powrie © Thomas S. G. Farnetti Wellcome

Wellcome is a global charitable foundation that funds thousands of researchers. It works with academia, philanthropy, businesses, governments, civil society and the public around the world to support science's role in solving health challenges.

With a background in immunology and translational research, Fiona has been a member of Wellcome's Board of Governors since January 2018. She will take up her post in January 2022 from Professor Mike Ferguson, who is stepping down from the Board and Wellcome after 10 years.

Following her appointment, Fiona said: "It is an honour and privilege to serve Wellcome as Deputy Chair. It's an organisation that I've always admired from the beginning of my career. I look forward to working with everyone at Wellcome to help deliver our new strategy that harnesses science and research to improve health for all."

Commenting on her appointment, Julia Gillard, Chair of Wellcome, said: "Fiona's new role as Deputy Chair will allow us to benefit even more from her experience in science and research. I look forward to working with her to drive forward Wellcome's mission to solve the urgent health challenges facing everyone."

Professor Andrew Carr, Head of Department at NDORMS, University of Oxford said: "We send our warm congratulations to Fiona on this new appointment. Fiona's pioneering work in immunology has contributed to a better understanding, prevention and treatment of disease which will help advance global scientific discovery research at Wellcome."

Similar stories

The Kennedy Institute launches its single cell facility

We spoke to Irina Udalova and Stephen Sansom about the Kennedy’s new single cell facility and how it will enhance research at the Institute and beyond.

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

The Kennedy’s research strongly endorsed following independent review

We recently welcomed our Scientific Advisory Board (SAB) and the Kennedy Trust Scientific Review Board (TSRB) to the Institute to review our current activities and future plans.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.

NIHR funding for musculoskeletal and inflammatory disease research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.